Title:

Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan

Africa: A Prospective, Multicenter Analysis from Uganda

Authors and Affiliations:

Jesse E. Ross MD,[1] Alin S. Tomoiaga PhD,[2] Nicholas Owor BA,[3] Xuan Lu MPH,[4] Joseph

Shinyale RN,[5] Tonny Kiyingi MBChB,[3] Ignatius Asasira MBChB,[3] Peter James Eliku

MS,[3] John Bosco Nsubuga MBChB,[5] Christopher Nsereko MBChB,[5] Irene Nayiga

MBChB,[5] Stephen Kyebambe MBChB,[5] Thomas Ochar MBChB,[6] Moses Kiwubeyi

DMLT,[6] Rittah Nankwanga RN,[6] Kai Nie MSc,[7] Hui Xie MSc,[7] Sam Miake-Lye MS,[7]

Bryan Villagomez BS,[7] Jingjing Qi MS,[7] Steven J Reynolds MD,[8,9,10] Martina Cathy

Nakibuuka MHS,[10] John Kayiwa MS,[3] Mercy Haumba BA,[3] Joweria Nakaseegu BS,[3]

Xiaoyu Che PhD, [11] Risa Hoffman MD,[12] John A Belperio,[1] Julius J. Lutwama PhD,[3]

Seunghee Kim-Schulze PhD,[7] Max R. O'Donnell MD,[4,11,13] Barnabas Bakamutumaho

MBChB,[3,14]† Matthew J. Cummings MD[4,11]†

[1]Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and
Immunology, David Geffen School of Medicine at University of California, Los Angeles,
CA, USA.

[2]Department of Accounting, Business Analytics, Computer Information Systems, and Law,
Manhattan College, New York, USA

[3]Department of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda
Virus Research Institute, Entebbe, Uganda

[4]Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine,
Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

[5]Entebbe Regional Referral Hospital, Ministry of Health, Entebbe, Uganda

[6]Tororo General Hospital, Ministry of Health, Tororo, Uganda

[7]Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York,
New York

[8]National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD, USA

[9]Johns Hopkins University School of Medicine, Baltimore, MD, USA

[10]Rakai Health Sciences Program, Kalisizo, Uganda

[11]Center for Infection and Immunity, Mailman School of Public Health, Columbia
University, New York, NY, USA

[12]Department of Medicine, Division of Infectious Diseases, David Geffen School of
Medicine at University of California, Los Angeles, USA.

[13]Department of Epidemiology, Mailman School of Public Health, Columbia University,
New York, NY, USA

[14]Immunizable Diseases Unit, Uganda Virus Research Institute, Entebbe, Uganda

†Co-senior authors

Corresponding Author: Jesse E Ross MD, MS, 200 UCLA Medical Plasa Ste 365B. Los
Angeles CA, 90095-8344

Funding: This work was supported by the National Heart Lung and Blood Institute
(5T32HL105323-08 to J.E.R), the National Institute of Allergy and Infectious Diseases
(K23AI16334 and R01AI184997 to M.J.C and the Division of Intramural Research
[S.J.R]), and the National Center for Advancing Translational Sciences (UL1TR001873 to
Columbia University, sub-award to M.R.O), National Institutes of Health. Additional
support was provided by the Burroughs Wellcome Fund /American Society of Tropical
Medicine and Hygiene (M.J.C), the Potts Memorial Foundation (J.E.R), and the Stony
Wold-Herbert Fund, Inc. (J.E.R). This research was support in part by the Intramural
Research Program of the NIH. The contributions of the NIH author(s) were made as part
of their official duties as NIH federal employees, are in compliance with agency policy
requirements, and are considered Works of the United States Government. However, the
findings and conclusions presented in this paper are those of the author(s) and do not
necessarily reflect the views of the NIH or the U.S. Department of Health and Human
Services.

<u>Abstract</u>

Background: Severe tuberculosis (TB) is a major cause of critical illness and death in
people living with HIV (PLWH) worldwide. Despite this, the immunopathology of severe
HIV-associated TB (HIV/TB) is poorly understood. We aimed to identify an
immunopathologic signature of severe HIV/TB in sub-Saharan Africa.

Setting: We analyzed proteomic data from two prospective observational cohorts of adults
hospitalized with severe undifferentiated infection in Uganda: an urban discovery cohort
(Entebbe, N=241) and a rural validation cohort (Tororo, N=253).

Methods: Soluble immune-related proteins were quantified in serum using Olink
proteomics. Participants were stratified into three HIV/TB phenotypes: HIV-negative
without TB, PLWH without TB, and PLWH with microbiologically diagnosed TB. We
applied ordinal random forest models in the discovery cohort to identify proteins strongly
predictive of progressive HIV/TB phenotype. The top 10 ranked proteins were then
analyzed using multivariable linear regression models in both the discovery and validation
cohorts to quantify their associations with HIV/TB phenotype.

Results: In both cohorts, PLWH with microbiologically diagnosed TB were at highest risk
of physiological instability and death. An eight-protein signature reliably distinguished this
phenotype, reflecting mediators of macrophage/dendritic cell activation (LAMP3), NK-
and T-cell stimulation and cytotoxicity (CD70, CRTAM), B-cell activation (IGLC2),
protease-mediated tissue injury (PRSS2), dysregulated coagulation (SERPINA5),
extracellular matrix remodeling (EFEMP1), and GH/IGF axis dysregulation (IGFBP3).

Conclusions: We identified an immunologic signature of severe HIV-associated TB
defined by mediators of macrophage/dendritic cell and cytotoxic lymphocyte activation,
extracellular matrix remodeling, and dysregulated coagulation. These findings offer new
insight into HIV/TB pathobiology and highlight potential targets for host-directed therapies
in this high-risk population.

Introduction:

Severe tuberculosis (TB) is the leading cause of hospitalization and death among people
living with HIV (PLWH) globally, with the highest TB burden in low- and middle-income
countries (1–4). In sub-Saharan Africa (SSA), where HIV and TB are co-epidemic, MTB
is the predominant cause of critical illness and death among hospitalized PLWH (5–6). In

this population, the frequency of disseminated MTB infection can exceed 40%, with short-

term mortality approaching 50% (6–9).

Despite this substantial burden, the immunopathology of severe HIV-associated

tuberculosis (HIV/TB) remains poorly understood. Few studies have characterized

multidimensional host responses in PLWH with severe TB, limiting insight into the

mechanisms driving immune dysfunction in this critically ill population and, consequently,

limiting the ability to target specific treatment mechanisms that may improve outcomes (1,

10 – 17). Available data suggests that MTB infection may be linked to activation of both

pro- and anti-inflammatory innate immune pathways, dysregulated T-cell activation and

exhaustion, endothelial dysfunction, and extracellular matrix remodeling (1, 10–17),

features that partially overlap with those observed in both HIV and critically ill patients

with non-TB bacterial infections (18–20). However, most studies to date have relied on

narrow biomarker panels, single-center designs, and lacked comparator groups such as

HIV-uninfected and TB-negative controls, which reduces immunologic resolution, hinders

attribution of TB-specific responses versus HIV or other critical illness, and limits

generalizability across settings (1, 10 – 17). Concurrently, emerging evidence from other

severe infections underscores substantial heterogeneity in host immune responses, shaped

not only by the pathogen but also by host-specific factors such as comorbidities and

immune status (19–21). In PLWH, chronic immune activation, T-cell exhaustion, and

endothelial dysfunction further influence host-pathogen interactions, potentially giving rise

to distinct immunopathologic signatures of critical illness (23–28). This biological

complexity underscores the need for higher-resolution immune profiling in severe

HIV/TB.

To address these gaps, we conducted high-throughput serum proteomic profiling in two

prospective hospital-based cohorts in Uganda to identify a reproducible immune signature

of severe HIV-associated TB. We hypothesized that hospitalized PLWH with severe TB

would exhibit a reproducible serum proteomic signature reflecting exaggerated innate

immune activation and T-cell exhaustion.

Methods

Study Settings, Outcomes, and Participants

We analyzed data from two prospective observational cohorts of adults hospitalized with severe febrile illness at two public hospitals in Uganda (**Figure 1**). The discovery cohort (RESERVE-U-1-EBB) was enrolled at Entebbe Regional Referral Hospital (ERRH), an urban referral hospital in central Uganda, between April 2017 and August 2019. The validation cohort (RESERVE-U-2-TOR) was enrolled at Tororo General Hospital (TGH), a rural district hospital in eastern Uganda, between November 2021 and August 2023. Enrollment criteria were uniform across the RESERVE-U cohorts. Non-pregnant adults (age ≥18 years) hospitalized with severe febrile illness (i.e., severe undifferentiated infection) were enrolled based on a reported history of fever or axillary temperature ≥ 37.5°C and illness severe enough to warrant admission. The primary clinical outcomes for RESERVE-U-1-EBB and RESERVE-U-2-TOR were 30- and 60-day vital status, respectively. Details of these cohorts have been published and are included in the supplement along with further details of study sites, procedures, and outcomes (18).

Study Procedures

Enrolled participants underwent standardized clinical assessments, including rapid testing for HIV by a Ministry of Health-recommended algorithm (29) and pathogens implicated as etiologies of severe infection in SSA, as informed by World Health Organization (WHO) guidelines (28). For PLWH, MTB testing included Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, CA, USA) on sputum samples and Determine TB-LAM (Abbott/Alere, Lake Bluff, IL, USA) on urine samples, where specimens were obtainable. TB testing of patients without HIV was at the discretion of treating clinicians.

Participants from both cohorts were individually categorized into one of three ordinal groups reflecting HIV/TB co-infection phenotypes: (1) HIV-negative and TB-negative (HIV-/TB-), (2) HIV-positive and TB-negative (HIV+/TB-), (3) HIV-positive and TB-positive (HIV+/TB+). Microbiological diagnosis of TB was based on a positive sputum Xpert MTB/RIF Ultra or urine TB-LAM result. HIV-uninfected participants were classified at TB-negative if sputum Xpert MTB/RIF Ultra was negative and there was no

clinical suspicion of TB. PLWH were classified as TB-negative if both sputum Xpert

MTB/RIF Ultra and urine TB-LAM results were negative and there was no clinical

suspicion of TB. In both cases, no clinical suspicion of TB was defined as the treating

clinicians' decision not to initiate empiric anti-TB therapy. Serum samples were collected

at the time of study enrollment and stored at –80°C until the time of analysis.

Olink Proteomics

Proteomic profiling was performed on cryopreserved serum samples using the Olink Target

Immunooncology and Cardiometabolic panels (Olink Proteomics AB, Uppsala, Sweden),

which together quantify concentrations of 184 soluble proteins (18). These panels were

utilized to capture multiple biological domains implicated in the host response to severe

infection (i.e., innate and adaptive immune activation, endothelial dysfunction, and

dysregulated coagulation), including severe TB. For each panel, proteins were quantified

via the Olink Proximity Extension Assay (PEA) platform, and relative protein abundance

was expressed in $\log_2$ normalized protein expression (NPX) units. Proteins were excluded

from downstream analyses if <20% of NPX values were above each panel's estimated limit

of detection (18).

Biomarker Selection Using Ordinal Forest Models

To identify soluble proteins associated with HIV/TB phenotypes, we applied an ordinal

random forest model to the RESERVE-U-1-EBB discovery cohort, using the three-level

HIV/TB phenotype classification as the ordinal outcome. To mitigate class imbalance and

optimize feature selection across all HIV/TB phenotypes, we performed class-balanced

upsampling through duplicating existing minority class samples, thereby equalizing group

representation during model training. Upsampling was restricted to the training data within

each resampling split, and the independent validation set was never upsampled. Random

forest model parameters included mtry = 5, nsets = 500, ntreeperdiv = 100, and nbest = 20.

The predictive strength of each protein was quantified using permutation-based variable

importance. The top ten proteins were selected from the importance rankings to provide a

parsimonious set of features that balances model interpretability with sufficient depth for

downstream analyses.

Multivariable Analysis of Soluble Proteins and HIV/TB Phenotypes

To quantify associations between soluble proteins and HIV/TB phenotypes, we analyzed the top 10 proteins identified in the RESERVE-U-1-EBB discovery cohort using separate multivariable linear regression models. Each model included NPX-quantified protein expression as the continuous outcome and HIV/TB phenotype as an ordinal predictor. Models were adjusted for age, sex, illness duration prior to enrollment, and malaria status. To avoid collider bias, we did not adjust for physiological severity, which may be influenced by both HIV/TB infection and host responses. We reported regression coefficients, 95% confidence intervals, and p-values for linear trend, correcting the latter for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) method. Proteins with FDR-adjusted p-values <0.05 in the RESERVE-U-1-EBB discovery cohort were carried forward for testing in the RESERVE-U-2-TOR validation cohort using identical regression models.

To explore whether proteomic associations with HIV/TB phenotypes were independent of HIV-related immunosuppression and/or viremia, we conducted a sensitivity analysis restricted to PLWH in the RESERVE-U-2-TOR cohort. We fit multivariable linear regression models for each of the top ten proteins, with NPX-quantified protein expression as the continuous outcome and HIV/TB phenotype as the ordinal predictor, adjusted for CD4 count and HIV-1 viral load. CD4 count was modeled as a continuous variable while HIV-1 viral load was modeled as a binary indicator: suppressed versus unsuppressed. Details of CD4 count and HIV-1 viral load quantification methods have been described and are in the supplement (**Table S1**) (18). Age, sex, illness duration, and malaria status were not included in this model to prevent overfitting and underpowering of this HIV-restricted exploratory analysis. Similarly, given the smaller sample size and exploratory intent, FDR correction was not applied and unadjusted p-values are reported. CD4 count and HIV-1 viral load data were unavailable from RESERVE-U-1-EBB participants.

All analyses were conducted in R version 4.3.2 using the tidyverse, ordinalForest, caret, stats, broom, and patchwork packages.

Ethics Statement

Each enrolled participant or their surrogate provided written informed consent. Study

protocols were approved by ethics committees at Columbia University (AAAR1450),

Uganda Virus Research Institute (GC/127/17/02-06/582), and Uganda National Council

for Science and Technology (HS2308).

Results

Participant Characteristics

A total of 494 participants were analyzed: 241 in the RESERVE-U-1-EBB (discovery)

cohort and 253 in the RESERVE-U-2-TOR (validation) cohort. Characteristics of analyzed

patients stratified by HIV/TB phenotype are presented in **Tables 1 and 2.** Approximately

half of participants were female. The median age was 32 years (IQR 26 – 40) in Entebbe

and 48 years (IQR 33 – 61) in Tororo. The proportion of PLWH was similar in Entebbe

and Tororo (51% versus 50% respectively), though the proportion of PLWH receiving anti-

retroviral therapy was higher in Tororo (83% versus 68%). In PLWH enrolled in

RESERVE-U-2-TOR, the median CD4 count was 350 cells/μL (IQR 300-600) and 71%

had suppressed HIV-1 viral loads (<150 copies/mL). The frequency of microbiologically

diagnosed TB was similar across sites: 21% in Tororo and 18% in Entebbe. Among those

with microbiologically diagnosed TB, disseminated disease as indicated by positive urine

TB-LAM testing was present in 40/47 (85%) of PLWH in Entebbe and 51/53 (96%) of

PLWH in Tororo. Mortality at 30- and 60-days was 22% in RESERVE-U-1-EBB and 26%

in RESERVE-U-2-TOR, respectively. Most deaths occurred after hospital discharge. In

both cohorts, PLWH with microbiologically diagnosed TB were at highest risk of

physiological instability and death.

Biomarker Results

After excluding 11 proteins due to high proportions of expression values below each Olink

panel's estimated limits of detection, we applied an ordinal random forest model in the

RESERVE-U-1-EBB discovery cohort to 173 soluble proteins. The top ten most important

proteins for prediction of HIV/TB phenotype reflected macrophage and dendritic cell

activation (LAMP3), NK and T-cell stimulation and cytotoxic function (CD70, CRTAM, IL-18), B cell activation and immunoglobulin production (IGLC2), protease-mediated tissue injury (PRSS2), dysregulated coagulation (SERPINA5), leukocyte adhesion and immune cell trafficking (ICAM3), extracellular matrix remodeling (EFEMP1), and growth hormone (GH) / insulin-like growth factor (IGF) axis dysregulation (IGFBP-3) (**Figure 2**).

In the RESERVE-U-1-EBB discovery cohort, all ten proteins were significantly associated with HIV/TB co-infection phenotype in multivariable linear regression models, including after FDR adjustment (**Figure 3A, Table S2**). Expression levels of eight proteins increased across the HIV-/TB-, HIV+/TB-, and HIV+/TB+ groups, while SERPINA5 and IGFBP-3 demonstrated an inverse association, with lower expression in participants with severe HIV/TB. In the validation cohort (RESERVE-U-2-TOR), eight of the ten proteins remained significantly associated with HIV/TB co-infection phenotype (**Figure 3B, Table S3**); associations for IL-18 and ICAM3 did not reach statistical significance. Visual inspection of boxplots confirmed consistent expression gradients across the HIV-/TB-, HIV+/TB-, and HIV+/TB+ groups in both cohorts (**Figures 4A and 4B**), with the most pronounced patterns observed for SERPINA5, LAMP3, and PRSS2.

In exploratory linear regression models restricted to PLWH in RESERVE-U-2-TOR and adjusted for CD4 count and HIV-1 viral load (N = 127), three proteins, EFEMP1, IGLC2, and SERPINA5, remained significantly associated with HIV/TB co-infection phenotype (**Figure 5, Table S4**).

Discussion

We identified and validated a proteomic immune signature associated with clinical phenotypes of HIV/TB in severely ill hospitalized adults in Uganda. To our knowledge, this is the first multicenter study in SSA to apply high-throughput proteomics to define and validate an immune signature of severe HIV-associated TB. These results advance translational understanding of immune dysregulation in a leading cause of critical illness and death among PLWH in the region. They also provide a foundation for biologically-

driven stratification of severe HIV-associated TB and could inform the design of biomarker-guided treatment strategies for this high-risk population.

Our findings align with contemporary models of TB pathogenesis that emphasize the balance between protective and pathological inflammation (30, 31). In the context of HIV, loss and dysfunction of CD4 T cells and antigen-presenting cells (APCs) compromise immune containment, permitting bacillary dissemination and multiorgan injury (30, 31). The immune signature identified in our study supports this framework with *in vivo* data from the global HIV/TB epicenter: LAMP3 reflects maturation/activation of macrophages and dendritic cells and heightened antigen presentation; CD70 and CRTAM reflect cytotoxic lymphocyte stimulation and potential exhaustion; IGLC2 denotes B-cell activation and heightened humoral response; PRSS2 and EFEMP1 implicate proteolytic tissue injury and extracellular matrix remodeling; lower SERPINA5 is consistent with unrestrained serine-protease activity and coagulation dysregulation leading to an immune-thrombotic milieu; and lower IGFBP-3 is associated with GH/IGF axis dysregulation, a pattern previously reported with AIDS-associated wasting and increasing severity of sepsis (32, 33). Collectively, these features define a reproducible HIV/TB signature linking APC activation, cytotoxic and humoral lymphocyte stimulation, tissue injury, disordered coagulation, and GH/IGF-axis perturbation.

Prior studies from South Africa have highlighted the complexity of immune dysregulation in PLWH with severe TB, characterized by simultaneous activation and exhaustion across innate and adaptive pathways (1, 11, 15). Using relatively low-dimensional cytokine profiling, one study showed that non-survivors exhibited elevated concentrations of both pro-inflammatory (CSF-3, TNF, IL-6) and anti-inflammatory (IL-1Ra) cytokines, alongside expansion of pro-inflammatory monocytes but impaired capacity of innate cells to mount cytokine responses to bacterial antigens (15). Broader cytokine panels have identified a clinically high-risk profile dominated by innate and chemotactic mediators (IL-6, IL-1Ra), whereas T-cell–associated mediators were inversely correlated with mortality (1). More recently, anemia, upregulation of matrix metalloproteinases (MMPs), and extracellular matrix turnover have also been linked with disease severity and poor outcomes in severe HIV/TB (11, 13).

A complementary study from South Africa in PLWH quantified circulating MTB burden using blood-based Xpert MTB/RIF Ultra and demonstrated a dose–response relationship between bacillary load, host-response signatures of inflammation and tissue damage, and mortality risk (12). Related work from our group in Uganda showed that higher urine TB-LAM grade, a marker of bacillary burden, was significantly associated with increased pro-inflammatory innate and T-cell activation and chemotaxis (10). Building on these findings, our 173-protein analysis provides a higher-resolution view of HIV/TB pathogenesis, revealing axes of immune dysregulation not captured by narrower cytokine panels. Specifically, we implicate APC activation (LAMP3), humoral activation (IGLC2), and cytotoxic-cell signaling (CD70, CRTAM), alongside extracellular matrix damage (EFEMP1), tissue injury (PRSS2), coagulation dysregulation (SERPINA5), and GH/IGF pathway disruption thereby extending the paradigm beyond pathogen load and broad inflammatory markers toward a more integrated host–pathogen framework. Additionally, our work demonstrates external validation across two hospitals with HIV-negative and TB-negative comparators, improving dissection of HIV/TB-specific biology across the clinical spectrum. Together, these findings point to a coordinated and multifaceted host response involving both innate and adaptive pathways, building on prior studies implicating immune activation in TB severity and poor outcomes among PLWH. In conjunction with pathogen-centric work, this motivates a combined pathogen-load plus host-response staging framework to inform risk stratification and potentially therapeutic trial design in severe HIV/TB.

Across the clinical spectrum of HIV/TB co-infection, the respective contributions of HIV and MTB to immune dysregulation, including mechanisms that drive illness severity, remain poorly defined (31, 34). Prior studies from South Africa have shown that HIV viremia and CD4 lymphocytopenia are associated with host inflammatory responses, with IL-17A, which was not included in our Olink panels, emerging as a central immunological mediator (30, 31, 34). In contrast, a prior study from Malawi showed that blunted TNF production in monocytes, suggesting innate immunoparalysis, was strongly predictive of poor outcomes in severe TB while HIV co-infection was not (17). In an exploratory analysis restricted to PLWH in the RESERVE-U-2-TOR cohort, three proteins reflecting B-cell activation and immunoglobulin production (IGLC2), dysregulated coagulation

(SERPINA5), and extracellular matrix remodeling (EFEMP1) remained significantly

associated with HIV/TB phenotype after adjustment for CD4 count and HIV-1 viral load.

These persistent associations suggest that although HIV-related immunosuppression and/or

viremia may contribute to immune dysregulation observed in our cohorts, it does not fully

account for the proteomic signature observed in severe HIV/TB. Nonetheless, given the

exploratory nature of this analysis, our results should be interpreted cautiously and

considered hypothesis-generating.

Beyond identifying an immune signature of severe HIV/TB, our findings advance

understanding of TB-specific immune responses, in contrast to those observed in other

severe HIV-associated infections (18–20). Prior analyses of the RESERVE-U cohorts

identified two pathobiologically-driven "Uganda Sepsis Signatures" (USS-1/USS-2), with

USS-2, enriched for severe HIV/TB and higher mortality, defined by myeloid cell and

inflammasome activation, T-cell exhaustion, endothelial barrier dysfunction and

prothrombotic imbalance (18). Our findings build on these insights, suggesting the

presence of a reproducible immunopathological signature specific to severe HIV-

associated TB in the global sepsis epicenter.

Our findings have direct relevance for the development of host-directed therapeutics in

severe HIV/TB. As diagnostic capabilities expand, protein-based signatures such as ours

could enable precise, biomarker-guided treatment strategies and support the design of

immunomodulatory treatment trials (12, 35). Several candidate therapies are already being

evaluated, including in randomized controlled trials. For example, corticosteroids in

NewStrat-TB aim to attenuate hyperinflammatory immune activation; doxycycline, a

known MMP inhibitor, may mitigate matrix injury and remodeling, as suggested by

preclinical and phase 2 data; aspirin targets the immunothrombotic axis, with signals of

safety and potential benefit demonstrated in TB meningitis (11, 36–39). Conceptually, a

parsimonious protein signature could be operationalized to enrich randomization in

ongoing or future host-directed treatment trials and serve as an early biomarker endpoint.

Moving forward, combining longitudinal proteomic profiling with quantitative pathogen

measurements could jointly stage bacillary burden and host response. In a serial sampling

study of disseminated HIV-associated TB, MTB DNA remained detectable in blood and

urine for up to 14 days after therapy initiation (40), underscoring the sustained
disseminated burden early in treatment and the potential value of pairing dynamic pathogen
and host-response data to refine therapeutic strategies.

Our study has several strengths. Our primary analysis was performed in two independent
prospective cohorts, across distinct geographic and temporal settings, encompassing nearly
500 hospitalized adults. These cohorts reflect real-world clinical populations at high risk
for HIV/TB co-infection and mortality, enhancing the translational relevance of our
findings. We employed a tiered analytical approach combining robust machine learning–
based feature selection with prespecified multivariable models and validation. By treating
HIV/TB phenotype as an ordinal variable, our models captured gradations in clinical and
microbiological phenotypes, rather than relying on binary group comparisons. Predictive
associations largely held across cohorts, increasing generalizability in high-burden
settings. The Olink platform enabled relatively high-throughput measurement of soluble
proteins across multiple biological domains. Importantly, several proteins retained
significant associations even after adjustment for CD4 count and viral load, suggesting
components of the signature reflect TB-specific immunopathology. Together, these
strengths support the biological plausibility, scalability, and external validity of the
identified immune signature.

Our study also has limitations. Although the two cohorts were geographically and
temporally distinct, we did not conduct external validation outside Uganda. However,
participant characteristics were broadly comparable to those of comparable cohorts in SSA
(41). While we included only microbiologically confirmed TB cases in the HIV+/TB+
group, undiagnosed or subclinical TB may have been present in the HIV-/TB- and
HIV+/TB- groups, potentially resulting in misclassification and attenuation of observed
differences biasing results towards the null. Although we attempted to adjust for co-
infections where data were available, including malaria, adjustment for cryptococcal and
other bacterial infections was not possible due to limited testing. Blood cultures were not
performed because of resource limitations. Therefore, residual confounding from
unmeasured or incompletely characterized infections is possible, and our signature may
reflect a more complex infectious background not limited to TB and HIV. We also did not

include a direct measure of circulating mycobacterial burden, which could have
strengthened our interpretation of immune activation patterns. Additionally, CD4 count
and HIV-1 viral load data were only available in the RESERVE-U-2-TOR cohort, limiting
adjustment for HIV disease severity in the discovery cohort. CD4 counts were multiply
imputed in a proportion of PLWH in RESERVE-U-2-TOR (18). However, we believe this
approach is justified, as simulation studies have demonstrated that multiple imputation
reduces bias compared to complete case analysis, even at higher levels of missingness than
our CD4 data (42). Proteomic data were collected at a single time point, which limits our
ability to assess dynamic immune responses over the course of illness or treatment. Finally,
our analysis focused on soluble protein expression, which may not fully reflect tissue-level
immune processes, particularly in lung or intra-cellular compartments central to TB
pathogenesis. Moreover, the Olink platform provides relative (NPX) assessments of
protein expression rather than absolute quantification, which may limit cross-platform
comparability.

In conclusion, we identified a reproducible eight-protein immune signature associated with
HIV/TB co-infection among severely ill hospitalized adults in Uganda. These findings
provide new insights into the immunopathology of severe HIV/TB in this high-risk
population and highlight potential candidate biomarkers that could support future
prognostic and therapeutic research.

Author Contributions

JER, BB, MRO'D, and MJC conceived the study and design. JJL, NO, CN, IN, SK, TO,
MK, RN, JK, MH, and JN collected, organized and entered clinical data and blood samples
and contributed to pathogen diagnostics. SKS, KN, HX, SML, BV contributed to proteomic
analyses. JER, MJC, AT, and XL had full access to all data in the study and contributed to
data cleaning, processing, verification, and analysis. JER developed the first draft of the
manuscript. JER, AT, NO, XL, JS, TK, IA, PJE, JBN, CN, IN, SK, TO, MK, RN, KN, HX,
SML, BV, JQ, SJR, MCN, JK, MH, JN, XC, WIL, RH, JAP, JJL, SKS, MRO, BB, MJC
reviewed and edited the final version of the manuscript. JER had final responsibility for
the decision to submit for publication.

<u>Declaration of Interests</u>

MJC reports consulting fees from Vertex Pharmaceuticals and Veracyte unrelated to the
submitted work. The remaining authors declare no conflicts of interest.

<u>Data sharing</u>

Proteomic data are available in Dryad at https://doi.org/10.5061/dryad.b2rbnzsq2. Analytic
code will be deposited in Github prior to publication.

References

1. Schutz C, Barr D, Andrade B, et al. Clinical, microbiologic, and immunologic determinants of
mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study.
PLoS Med. 2019;16(7): e1002840.
2. UNAIDS. Fact sheet—World Tuberculosis Day 2022. Geneva, Switzerland: Joint United Nations
Programme on HIV/AIDS; 2022. Available at: https://www.unaids.org.
3. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality
among people living with HIV worldwide: a systematic review and meta-analysis. *J Int AIDS Soc*.
2016;19(1):20714.
4. World Health Organization. Global tuberculosis report 2022. Geneva, Switzerland: World Health
Organization; 2022. Available at: https://www.who.int.

5. Rudd K, Johnson S, Agesa K, et al. Global, regional, and national sepsis incidence and mortality,
1990–2017: analysis for the Global Burden of Disease Study. *Lancet.* 2020;395:200–211.
6. Cummings M, O'Donnell M. Inverting the pyramid: increasing awareness of mycobacterial sepsis
in sub-Saharan Africa. *Int J Tuberc Lung Dis.* 2015;19(10):1128–1134.
7. Reddy E, Shaw A, Crump J. Community-acquired bloodstream infections in Africa: a systematic
review and meta-analysis. *Lancet Infect Dis.* 2010;10(6):417–32.
8. Barr D, Lewis J, Feasey N, et al. *Mycobacterium tuberculosis* bloodstream infection prevalence,
diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-
analysis of individual patient data. *Lancet Infect Dis.* 2020;20(6):742–752.
9. Gupta R, Lucas S, Fielding K, et al. Prevalence of tuberculosis in post-mortem studies of HIV-
infected adults and children in resource-limited settings: a systematic review and meta-analysis.
AIDS. 2015;29(15):1987–2002.
10. Cummings M, Bakamutumaho B, Jain K, et al. Detection of urine lipoarabinomannan is associated
with proinflammatory innate immune activation, impaired host defense, and organ dysfunction in
adults with severe HIV-associated tuberculosis in Uganda. *J Acquir Immune Defic Syndr.*
2023;93(1):79–85.
11. Walker N, Schutz C, Ward A, et al**.** Elevated plasma matrix metalloproteinases associate with
Mycobacterium tuberculosis bloodstream infection and mortality in HIV-associated tuberculosis. *J
Infect Dis.* 2025;231(1):109–114
12. Boloko L, Schutz C, Sibiya N, et al. Xpert Ultra testing of blood in severe HIV-associated
tuberculosis to detect and measure *Mycobacterium tuberculosis* bloodstream infection: a
diagnostic and disease biomarker cohort study. *Lancet Microbe.* 2022;3(7):e521–e532.
13. Araújo-Pereira M, Schutz C, Barreto-Duarte B, et al. Interplay between systemic inflammation,
anemia, and mycobacterial dissemination and its impact on mortality in TB-associated HIV: a
prospective cohort study. *Front Immunol.* 2023;14:1177432.
14. Ravimohan S, Tamuhla N, Steenhoff A, et al. Immunological profiling of tuberculosis-associated
immune reconstitution inflammatory syndrome and non-IRIS death in HIV-infected adults with
pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.
Lancet Infect Dis. 2015;15(4):429–438.
15. Janssen S, Schutz C, Ward A, et al**.** Mortality in severe human immunodeficiency virus–
tuberculosis associates with innate immune activation and dysfunction of monocytes. *Clin Infect
Dis.* 2017;65(1):73–82.
16. Clark D, Banura P, Bandeen-Roche K, et al. Biomarkers of endothelial activation/dysfunction
distinguish subgroups of Ugandan patients with sepsis and differing mortality risks. *JCI Insight.*
2019;5(10):e127623.
17. Waitt C, Banda N, White S, et al. Early deaths during tuberculosis treatment are associated with
depressed innate responses, bacterial infection, and tuberculosis progression. *J Infect Dis.*
2011;204(3):358–62.
18. Cummings M, Lutwama J, Owor N, et al. Unsupervised classification of the host response
identifies dominant pathobiological signatures of sepsis in sub-Saharan Africa. *Am J Respir Crit
Care Med.* 2025;211(3):357–369.
19. Reddy K, Sinha P, O'Kane C, et al. Subphenotypes in critical care: translation into clinical
practice. *Lancet Respir Med.* 2020;8(6):631–643.
20. van der Poll T, Shankar-Hari M, Wiersinga W. The immunology of sepsis. *Immunity.*
2021;54(11):2450–2464
21. Singer M, Deutschman C, Seymour C, et al. The third international consensus definitions for
sepsis and septic shock (Sepsis-3). *JAMA.* 2016;315:801–810.
22. Schutz C, Meintjes G, Almajid F, et al. Clinical management of tuberculosis and HIV-1 co-
infection. *Eur Respir J.* 2010;36(6):1460–81.
23. Kanmogne GD. HIV infection, antiretroviral drugs, and the vascular endothelium. *Cells.*
2024;13(8):672.
24. Mu W, Patankar V, Kitchen S, et al. Examining chronic inflammation, immune metabolism, and T
cell dysfunction in HIV infection. *Viruses.* 2024;16(2):219.

25. Walker N, Meintjes G, Wilkinson R. HIV-1 and the immune response to TB. *Future Virol.* 2013;8(1):57–80.

26. Cummings M, Bakamutumaho B, Price A, et al. HIV infection drives pro-inflammatory immunothrombotic pathway activation and organ dysfunction among adults with sepsis in Uganda. *AIDS.* 2023;37:233–245.

27. Hunt P, Lee S, Siedner M. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. *J Infect Dis.* 2016;214(Suppl 2):S44–S50.

28. World Health Organization. IMAI district clinician manual: hospital care adolescents and adults. Geneva, Switzerland: World Health Organization; 2012. Available at: https://www.who.int/publications/i/item/imai-district-clinician-manual-hospital-care-adolescents-and-adults.

29. Ministry of Health. National HIV Testing Services Policy and Implementation Guidelines: Uganda. 4th Edition. October 2016. Available at: https://library.health.go.ug/sites/default/files/resources/UGANDA%20HTS%20POLICY%20AND%20IMPLEMENTATION%20GUIDELINES%202016%20%282%29.pdf

30. Scriba T, Maseeme M, Young C, et al. Immunopathology in human tuberculosis. *Sci Immunol.* 2024;9(102):eado5951.

31. Meintjes G, Maartens G. HIV-associated tuberculosis. *N Engl J Med.* 2024;391(4):343–355.

32. Frost R, Fuhrers J, Steigbigels R, et al. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. *Clinical Endocrinology.* 1996;44:501-514

33. Papastathi C, Mavrommatis A, Mentzelopoulos S, et al. Insulin-like growth factor I and its binding protein 3 in sepsis. *Growth Hormone & IGF Research*. 2013;23(4):98-104.

34. Du Bruyn E, Fukutani K, Rockwood N, et al. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. *Lancet Microbe.* 2021;2(8):e375–e385.

35. Ross J, Cummings M, Bakamutumaho B, et al. Xpert MTB/RIF Ultra enables sensitive detection of *Mycobacterium tuberculosis* in blood. *Int J Tuberc Lung Dis.* 2024;28(12):594–596.

36. Namale P, Boloko L, Vermeulen M, et al. Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial. *Trials.* 2024;25(1):311.

37. Miow Q, Vallejo A, Wang Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. *J Clin Invest.* 2021;131(15):e141895.

38. Walker N, Clark S, Oni T, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. *Am J Respir Crit Care Med.* 2012;185(9):989–997.

39. Rohilla R, Shafiq N, Malhotra S. Efficacy and safety of aspirin as an adjunctive therapy in tubercular meningitis: a systematic review and meta-analysis. *EClinicalMedicine.* 2021;34:100819.

40. Boloko L, Vermeulen M, Sossen B, et al. Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis. *S Afr J HIV Med.* 2025;26(1):1664.

41. Lewis JM, Feasey NA, Rylance J. Aetiology and outcomes of sepsis in adults in sub-Saharan Africa: a systematic review and meta-analysis. *Crit Care.* 2019;23:212.

42. Madley-Dowd P, Hughes R, Tilling K, et al. The proportion of missing data should not be used to guide decisions on multiple imputation. *J Clin Epidemiol.* 2019;110:63–73.

546   **Table 1: Participant characteristics stratified by HIV/TB phenotype in RESERVE-**
547   **U-1-EBB cohort.**

Characteristics [a]	All participants N = 241	HIV - / TB - N = 117	HIV + / TB - N = 77	HIV + / TB + N=47
Demographics				
Female sex	149/241 (62%)	71/117 (61%)	52/77 (68%)	26/47 (55%)
Age, years	32 (26, 40)	28 (23, 38)	37 (30, 43)	32 (27, 40)
Mid-upper arm circumference, cm	--	--	--	--
Illness duration prior to enrollment, days	4 (2, 6)	3 (2, 5)	4 (3, 7)	6 (3, 7)
Clinical signs and physiological severity scores				
KPS at hospital admission	--	--	--	--
Whole-blood lactate, mmol/L	--	--	--	--
qSOFA score $\geq$ 2[b]	139/241 (58%)	87/117 (74%)	38/77 (49%)	14/47 (30%)
Modified Early Warning Score	3 (2, 4)	3 (2, 3)	3 (2, 4)	5 (3, 6)
Universal Vital Assessment score	2 (1, 4)	1 (0, 2)	3 (2, 5)	3 (3, 7)
HIV Characteristics				
PLWH	124/241 (51%)	NA	77/77 (100%)	47/47 (100%)
WHO HIV clinical stage 3 or 4	97/124 (78%)	NA	50/77 (65%)	47/47 (100%)
Receiving ART before hospitalization	73/124 (59%)	NA	45/77 (58%)	28/47 (60%)
CD4 cell count (cells/mm^3)	--	--	--	--
HIV-1 viral suppression	--	--	--	--
Pathogen diagnostics				
Malaria RDT positive	54/237 (23%)	30/116 (26%)	20/76 (26%)	4/45 (8.9%)
Urine TB-LAM positive if PLWH	40/99 (40%)	NA	NA	40/47 (85%)
Cryptococcal ag. positive if PLWH	9/29 (31%)	NA	6/13 (46%)	3/16 (19%)
Influenza PCR positive	14/219 (6.4%)	8/106 (7.5%)	5/71 (7.0%)	1/42 (2.4%)
Outcomes				
Death in hospital	14/241 (5.8%)	4/117 (3.4%)	4/77 (5.2%)	6/47 (13%)

Death at 30 days	49/219 (22%)	10/106 (9.4%)	20/68 (29%)	19/45 (42%)

Abbreviations:, KPS: Karnofsky Performance Status, qSOFA: quick Sepsis-related Organ Failure Assessment, PLWH: person living with HIV; WHO: World Health Organization, ART: anti-retroviral therapy, RDT: rapid diagnostic test, TB: tuberculosis, LAM: lipoarabinomannan, PCR: polymerase chain reaction

Legend: [a]Dichotomous and categorical variables summarized as counts (proportions), continuous variables summarized as medians (interquartile ranges), n if fewer patients with available data than the total number of patients in the cohort; [b]Systolic blood pressure ≤100mmHg, respiratory rate ≥22 breaths/min, and altered mental status, latter defined using

575   **Table 2: Participant characteristics stratified by HIV/TB phenotype in RESERVE-**
576   **U-2-TOR cohort.**

Characteristics [a]	All participants N = 253	HIV - / TB - N = 126	HIV + / TB - N = 73	HIV + / TB + N=54
Demographics				
Female sex	158/253 (62%)	84/126 (67%)	39/73 (53%)	35/54 (65.0%)
Age, years	48 (33, 61)	48 (25, 70)	47 (40, 56)	48 (40, 56)
Mid-upper arm circumference, cm	24 (22, 26)	24 (23, 26)	24 (23, 26)	22 (20, 24)
Illness duration prior to enrollment, days	6 (4, 10)	6 (4, 9)	7 (4, 10)	9 (4, 14)
Clinical signs, lactate, and physiological severity scores				
KPS at hospital admission	60 (20, 70)	70 (20, 80)	60 (40, 70)	50 (20, 70)
Whole-blood lactate, mmol/L	2.4 (1.8, 3.0)	2.4 (1.8, 3.0)	2.4 (1.7, 2.9)	2.4 (2.0, 3.0)
qSOFA score ≥ 2 [b]	100/253 (40%)	46/126 (37%)	29/73 (40%)	25/54 (46%)
Modified Early Warning Score	3 (2, 5)	3 (2, 5)	4 (2, 5)	3 (2, 5)
Universal Vital Assessment score	2 (1, 5)	1 (0, 4)	3 (2, 6)	4 (2, 6)
HIV Characteristics				
PLWH	127/253 (50%)	NA	73/73 (100%)	54/54 (100%)
WHO HIV clinical stage 3 or 4	93/127 (73%)	NA	51/73 (70%)	42/54 (78%)
Receiving ART before hospitalization	105/127 (83%)	NA	57/73 (78%)	48/54 (89%)
CD4 count, cells/mm^3	350 (300, 600)	NA	400 (300, 600)	344 (200, 500)
HIV-1 viral suppression	85/120 (71%)	NA	49/68 (72%)	36/52 (69%)
Pathogen diagnostics				
Malaria RDT positive	74/253 (29%)	41/126 (33%)	18/73 (25%)	15/54 (28%)
Urine TB-LAM positive	51/122 (42%)	NA	0/69 (0%)	51/53 (96%)
Cryptococcal ag. positive if PLWH	10/123 (8.1%)	NA	6/70 (8.6%)	4/53 (7.5%)
Influenza PCR positive	14/246 (5.7%)	9/123 (7.3%)	5/72 (6.9%)	0/51 (0%)
SARS-CoV-2 PCR positive	13/246 (5.3%)	8/123 (6.5%)	1/72 (1.4%)	4/51 (7.8%)
Outcomes				
Death in hospital	5/253 (2.0%)	1/126 (0.8%)	1/73 (1.4%)	3/54 (5.6%)

Death at 30 days	51/252 (20%)	11/126 (8.7%)	15/72 (21%)	25/54 (46%)
Death at 60 days	65/252 (26%)	18/126 (14%)	19/72 (26%)	28/54 (52%)

Figure 1. Overview of study design and analytical workflow for proteomic signature discovery and validation.

Figure 2. Bar plot of top 10 proteins most predictive of HIV/TB phenotype in the
RESERVE-U-1 EBB discovery cohort. Proteins ranked in descending order of
permutation-based variable importance as derived from ordinal random forest models (N
= 241).

Adjusted association of biomarkers with HIV/TB phenotype (RESERVE-U-1-EBB)

Figure 3A. Forest plot showing adjusted regression coefficients and 95% confidence
intervals (CI) for the association between HIV/TB phenotype and protein expression in
the RESERVE-U-1-EBB discovery cohort. Coefficients and 95% CIs generated from
linear regression models including NPX-quantified protein expression as the continuous
outcome and HIV/TB phenotype as an ordinal predictor, adjusted for age, sex, illness
duration prior to enrollment, and malaria status (N = 241).

Figure 3B. Forest plot showing adjusted regression coefficients and 95% confidence
intervals (CI) for the association between progressive HIV/TB phenotype and protein
expression in the RESERVE-U-2-TOR validation cohort. Coefficients and 95% CIs
generated from linear regression models including NPX-quantified protein expression as
the continuous outcome and HIV/TB phenotype as an ordinal predictor, adjusted for age,
sex, illness duration prior to enrollment, and malaria status (N = 253).

Protein expression across HIV/TB phenotype (RESERVE-U-1-EBB)

655
656 **Figure 4A**. Boxplots showing distribution of top 10 most predictive proteins across
657 HIV/TB phenotypes in RESERVE-U-1-EBB discovery cohort (N = 241).

Protein expression across HIV/TB phenotype (RESERVE-U-2-TOR)

Figure 4B. Boxplots showing distribution of top 10 most predictive proteins across HIV/TB phenotypes in RESERVE-U-2-TOR validation cohort (N = 253).

Figure 5. Forest plot of regression coefficients for the association between HIV/TB
phenotype and protein expression in PLWH in RESERVE-U-2-TOR cohort. Each model
included NPX-quantified protein expression as the continuous outcome and HIV/TB
phenotype as an ordinal predictor. Models were adjusted for CD4 count and HIV-1 viral
load suppression (N = 127).